Glycine-site antagonists and stroke

Bibliography

• HOLLMAN M, HEINEMANN S: Cloned glutamate receptors. Ann. Rev. Neurosci. (1994) 17:31–108.
   PubMed Web of Science ®Google Scholar
• •Review of molecular biology of glutamate receptors. HENLEY HM, BRUTON R, RICHMOND SA: Metabotropic glutamate receptors. Front. Neurobiol (1998) 3:113–118.
   Google Scholar
• •Review of biology regarding the mGluR receptors. SCHNEGGENBURGER R, ZHOU Z, KONNERTH A, NEHER E: Fractional contribution of calcium to the cation current glutamate receptor channels. Neurone (1993) 11:133–143.
   Google Scholar
• BEHE P, STERN P, WYLLIE DJA, NASSAR M, SCHOEPFER R,COLQUHOUN D: Determination of NMDA NR1 subunit copy number in recombinant NMDA receptors. Proc. Roy. Soc. Lond. Ser. B. (1995) 262:205–213.
   PubMed Web of Science ®Google Scholar
• LAUBE B, KUHSE J, BETZ H: Evidence of a tetramericstructure of recombinant NMDA receptors. J. Neurosci. (1998) 18: 2954–2961.
   PubMed Web of Science ®Google Scholar
• •Description of experiments devoted to the demonstration of the tetrameric proteinic structure of the NMDA receptors composed of 4 homologous subunits.
   Google Scholar
• DURAND GM, BENNETT MVL, ZUKIN RS: Splice variantsof the N-methyl-D-aspartate receptor NR1 identify domains involved in regulation by poliamines and protein kinase C. Proc. Natl. Acad. Sci. USA (1993) 90:6731–6735.
   PubMedGoogle Scholar
• ZUKIN RS, BENNETT MVL: Alternative spliced isoformsof the NMDAR1 receptor subunit. Trends Neurosci. (1995) 18:306–313.
   PubMed Web of Science ®Google Scholar
• •Interesting work of molecular biology.
   Google Scholar
• LEESON PD, IVERSEN LL: The glycine site on the NMDA receptor: structure-activity relationships and therapeutical potential. J. Med. Chem. (1994) 37:4053–4067.
   PubMed Web of Science ®Google Scholar
• ••Detailed description of the glycine receptor together with acomprehensive survey on SAR and biological profile of the first series of tetrahydroquinolines.
   Google Scholar
• LYNCH DR, ANEGAWA NJ, VERDROON T, PRITCHETT DB:N-methyl-D-aspartate receptors: different subunit requirements for binding of glutamate antagonists, glycine antagonists, and channel-blocking agents. Mol. Pharmacol (1994) 45:540–545.
   PubMed Web of Science ®Google Scholar
• JOHNSON JW, ASCHER P: Glycine potentiates the NMDAresponse in cultured mouse brain neurons. Nature (1987) 325:529–531.
   PubMed Web of Science ®Google Scholar
• •Disclosure of the importance of glycine in potentiation of the NMDA receptor responses.
   Google Scholar
• CARTER AJ: Glycine antagonists: regulation of the NMDA receptor-channel complex by the strychnine-insensitive glycine site. Drugs Future (1992) 17:595–613.
   Google Scholar
• ••Review on glycine antagonists including the chemicalcompounds disclosed until that date and their possible therapeutic indications.
   Google Scholar
• KEMP JA, LEESON PD: The glycine site of the NMDAreceptor-five years on. Trends Pharmacol Sci. (1993) 14:20–25.
   PubMed Web of Science ®Google Scholar
• HIRAI H, KIRSCH J, LAUBE B, BETZ H, KUHSE J: Theglycine binding site of the N-methyl-D-aspartate receptor subunit NR1: Identification of novel determi-nants of co-agonist potentiation in the extracellularM3-M4 loop region. Proc. Natl. Acad. ScL USA (1996) 93:6031–6036.
   PubMed Web of Science ®Google Scholar
• DANYSZ W, PARSONS CG: Glycine and N-Methyl-D-Aspartate receptors: physiological significance and possible therapeutic Applications. Pharmacol. Rev. (1998) 50:597–664.
   PubMed Web of Science ®Google Scholar
• ••Review on the new data related to the role of glutamate inCNS disorders.
   Google Scholar
• HONER M, BENKE D, LAUBE B et al.: Differentiation of glycine antagonist sites of N-Methyl-D-aspartate receptor subtypes. J Biol. Chem. (1998) 18:11158–11163.
   Google Scholar
• BENKE D, HONER M, HECKENDORN R et al.: rHICGP 61594, the first photoaffinity ligand for the glycine site of NMDA receptors. Neuropharmacology (1999) 38:233–242.
   PubMed Web of Science ®Google Scholar
• JOHNSON JVV, ASCHER P: Voltage-dependent block by intracellular Mg of N-methyl-D-aspartate-activated channels. Biophys. 1 (1990) 57:1085-1090.
   Google Scholar
• PARSONS CG, DANYSZ W, QUACK G: Glutamate in CNS Disorders as a target for drug development: an update. Drug News Perspect. (1998) 11:523–569.
   PubMed Web of Science ®Google Scholar
• ••Review on the new data related to the role of glutamate inCNS disorders.
   Google Scholar
• DANNHARDT G, KOHL BK: The glycine site on the NMDA receptor: structure-activity relationships and possible therapeutic applications. Curr. Med. Chem. (1998) 5: 253–263.
   PubMed Web of Science ®Google Scholar
• ELKIND MS, SACCO RL: Stroke Risk Factors and StrokePrevention. In: Seminars in Neurology Third Edition (1998) 18:429–440.
   PubMed Web of Science ®Google Scholar
• •Review on the various risk factors for stroke.
   Google Scholar
• HORN J, BOUWERS PJAM, LIMBURG M: Disturbances incalcium homeostasis in ischaemic stroke. CNS Drugs (1999) 11:373–386.
   Web of Science ®Google Scholar
• COTMAN CW, FOSTER AC, LANTHORN TH: An overviewof glutamate as neurotransmitters. Adv. Biochem. Psychopharmacol. (1981) 27:1–27.
   PubMedGoogle Scholar
• WATKINS JC, EVANS RH: Excitatory aminoacids transmitters. Ann. Rev. Pharmacol. Toxicol. (1981) 21:165–204.
   PubMed Web of Science ®Google Scholar
• CHOI DW, ROTHMAN SM: The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Ann. Rev. Neurosci. (1991) 31: 171–182.
   Google Scholar
• •Review that suggests the role of glutamate neurotoxicity in ischaemia.
   Google Scholar
• WOOD PL, HAWKINSON JE: N-methyl-D-aspartate antagonists for stroke and head trauma. Exp. Opin. Invest. Drugs (1997) 6:389–397.
   PubMedGoogle Scholar
• HICKENBOTTOM SL, GROTTA J: Neuroprotective Therapy. In Seminars in Neurology Third Edition (1998)18: 485–492. Review on the possible therapeutic approach to stroke.
   Google Scholar
• SMALL DL, MORLEY P, BUCHAN AM: Preclinical studies of glutamate receptor antagonists for the treatment of cerebral ischemia. In: Stroke Therapy. Basic, Preclinical and Clinical Directions. Miller LP (Eds.) (1999):65–99.
   Google Scholar
• GLOBUS MYT, BUSTO R, MARTINEZ E et al.: Comparative effect of transient global ischemia on extracellular levels of glutamate, glycine, and y-aminobutyric acid in vulnerable and nonvulnerable brain regions in the rat. J. Neurochem. (1991) 57:470–478.
   PubMed Web of Science ®Google Scholar
• MCCULLOCH J, IVERSEN LL: Autoradiographic assess-ment of the effects of N-Methyl-D-Aspartate (NMDA) receptor antagonists in vivo. Neurochem. Res. (1991) 16:951–963.
   PubMed Web of Science ®Google Scholar
• •Review on the contribution of this technique to the understanding of CNS activity of the NMDA antagonists.
   Google Scholar
• HARGREAVES RJ, RIGBY M, SMITH D, HILL RG, IVERSEN LL: Competitive as well as uncompetitive N-methyl-D-Aspartate receptor antagonists affect cortical neuronal morphology and cerebral glucose metabolism. Neurochem. Res. (1993) 18:1263–1269.
   PubMed Web of Science ®Google Scholar
• HARGREAVES RJ, RIGBY M, SMITH D, HILL RG: Lack of effect of L-687,414 ((+)-cis-4-methyl HA-966) on NMDA receptor antagonist acting at the glycine site, on cerebral glucose metabolism and cortical neuronal morphology. Br. J. Pharmacol. (1993) 110:36–42.
   PubMed Web of Science ®Google Scholar
• KULAGOWSKI JJ, LEESON PD: Glycine-site NMDA receptor antagonists. Exp. Opin. Ther. Patents (1995) 5: 1061–1075.
   Google Scholar
• ••Review on glycine antagonists published before July 1995.
   Google Scholar
• BIGGE CF, MALONE TC: Agonists, antagonists and modulators of the N-methyl-D-aspartic acid (NMDA) anda-amino-3-hydroxy-5-methy1-4--isoxazolepropanoic acid (AMPA) subtypes of glutamate receptors. Curr. Opin. Ther. Patents (1993):951–989.
   Google Scholar
• KEMP JA, FOSTER AC, LEESON PD et al.:7-chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex. Proc. NatL Acad. ScL USA (1988) 85:6547–6550.
   PubMed Web of Science ®Google Scholar
• SALITURO FG, HARRISON BL, BARON BM et al.:3-(2-Carboxyindo1-3-yfipropionic acid-based antago-nists of the N-methyl-D-aspartic acid receptor associ-ated glycine binding site. J. Med. Chem. (1992) 35: 1791–1799.
   PubMed Web of Science ®Google Scholar
• DI FABIO R, CAPELLI AM, CONTI N et al.: Substitutedindole-2-carboxylates as in vivo potent antagonists acting as the strychnine-insensitive glycine binding site. J. Med. Chem. (1997) 40:841–850.
   PubMed Web of Science ®Google Scholar
• •Detailed description of the SAR and biological profile of the second series of tetrahydroquinolines.
   Google Scholar
• DI FABIO R, CUGOLA A, DONATI D et al. Identification and pharmacological characterization of GV150526, anovel glycine antagonist as a potent neuroprotective agent. Drugs of the Future (1998) 23: 61–69. Complete pharmacological characterisation of GV150526.
   Google Scholar
• BORDI F, PIETRA C, ZIVIANI L, REGGIANI A: The glycine antagonist GV150526 Protects somatosensory evoked potentials and reduces the infarct area in the MCAo model of focal ischemia in the rat. Exp. Neurol (1997) 145:425–433.
   PubMed Web of Science ®Google Scholar
• DYKER AG, LEES KR: Safety and tolerability of GV150526 (a glycine site antagonist at the N-Methyl-D-Aspartate Receptor) in patients with acute stroke. Stroke (1999) 30:986–992.
   PubMed Web of Science ®Google Scholar
• GIACOBBE SA, BARALDI D, DI FABIO R: Unusual synthesis of new glycine antagonists via sequential aldol condensation-lactonization-elimination reaction. Bioorg. Med. Chem. Lett. (1998) 8:1689–1692.
   PubMed Web of Science ®Google Scholar
• DI FABIO R, ANTOLINI M, BERTANI B et al: SAR and neuroprotective activity of a novel class of glycine antagonists. In: Book of Abstracts 217th ACS National Meeting, Anaheim, California, USA March 21–25 (1999).
   Google Scholar
• BALSAMINI C, BEDINI A, DIAMANTINI G et al.: (E)-3-(2-N-PhenylcarbamoyDvinyl)pyrrole-2-carboxylic acid derivatives, a novel class of glycine site antagonists. J. Med. Chem. (1998) 41:808–820.
   PubMed Web of Science ®Google Scholar
• KEANA JFW, KHER SM, CAI SX et al.: Synthesis and structure-activity relationships of substituted 1,4-Dihydroquinoxaline-2,3-diones: antagonists of /V-methyl-D-aspartate (NMDA) receptor glycine sites and non-NMDA glutamate receptors. J. Med. Chem. (1995) 38:4367–4379.
   PubMed Web of Science ®Google Scholar
• ••Detailed description of the SAR and biological profile of thequinoxalinediones.
   Google Scholar
• WOODWARD RM, HUETTNER JE, GUASTELLA J, KEANA JFW, WEBER E: In vitro pharmacology of ACEA-1021 and ACEA-1031: sistematically active quinoxalinedio-nes with high affinity and selectivity for N-methyl-D--aspartate receptor glycine sites. Molec. Pharmacol. (1995) 47:568–581.
   PubMed Web of Science ®Google Scholar
• PEARLSTEIN RD, BEIRNE JP, MASSEY GW, WARNER DS: Neuroprotective effects of NMDA Receptor glycine recognition site antagonism: dependence on glycine concentration. J. Neurochem. (1998) 70:2012–2019.
   PubMed Web of Science ®Google Scholar
• WARNER DS, MARTIN H, LUDWIG P, McALLISTER A, KEANA JFW, WEBER E: In vivo models of cerebral ischemia: effects of parenterally administered NMDA receptor glycine site antagonists. J. Cerebral Blood Flow and Metabolism (1995) 15:188–196.
   PubMed Web of Science ®Google Scholar
• LINGENHOEHL K, POZZA MF: Reevaluation of ACEA1021 as an antagonist at the strychnine-insensitive glycine site of the N-methyl-D-aspartate receptor. Neuropharmacol (1998) 37:729–737.
   PubMed Web of Science ®Google Scholar
• ALBERS GW, CLARK WM, ATKINSON RP et al.: Dose escalation study of the NMDA glycine-site antagonist licostinel in acute ischemic stroke. Stroke (1999) 30:508–513.
   PubMed Web of Science ®Google Scholar
• •Studies on the safety and tolerability of ACEA1021.
   Google Scholar
• CAI SX, KHER SM, ZHOU ZL et al: Structure-activity relationships of Alkyl- and Alkoxy-Substituted1,4-dihydroquinoxaline-2,3-diones: potent and systemically active antagonists for the glycine site of the NMDA receptor. J. Med. Chem. (1997) 40: 730–738.
   PubMed Web of Science ®Google Scholar
• ••Detailed description of the biological profile of thequinoxalinediones structurally related to ACEA1021.
   Google Scholar
• ILYIN VI, WHITTEMORE ER, TRAN Metal: Pharmacologyof ACEA-1416: a potent sistemically active NMDA receptor glycine site antagonist. Eur. J. Pharmacol (1996) 310:107–114.
   PubMed Web of Science ®Google Scholar
• NAGATA R, TANNO N, KODO T et al.: Tricyclic quinoxalinediones: 5,6-dihydro -1H-pyrrolo[1,2,3-de] quinoxaline-2,3-diones and 6,7-dihydro-1H,5H-pyrido[1,2,3-de]quinoxaline-2,3-diones as potent antagonists for the glycine binding site of the NMDA receptor. J. Med. Chem. (1994) 37:3956–3968.
   PubMed Web of Science ®Google Scholar
• ••Detailed description of the biological profile of thequinoxalinediones structurally belonging to the Sumitomo series of quinazolinediones.
   Google Scholar
• MARUOKA Y, OHNO Y, TANAKA H et al.: Effect of thenovel tricyclic quinoxalinedione derivatives, SM-18400 and its analogs, on /V-methyl-D-aspartate (NMDA) receptor-mediated synaptic transmission in the isolated neonatal rat spinal cord In vitro. Jpn. J. Pharmacol (1998) 76: 265–270.
   PubMedGoogle Scholar
• ACKLIN P, ALLGEIER H, AUBERSON YP et al.:5-aminomethylquinoxaline-2,3-diones, Part III: arylamide derivatives as highly potent and selective glycine-site NMDA receptor antagonists. Bioorg. Med. Chem. Lett. (1998) 8:493–498.
   PubMed Web of Science ®Google Scholar
• AUBERSON YP, ACKLIN P, ALLGEIER H et al.:5-Aminomethylquinoxaline-2,3-diones. Part II: N-Aryl derivatives as novel NMDA/glycine and AMPA antago-nists. Bioorg. Med. Chem. Lett. (1998) 8:71–74.
   Google Scholar
• AUBERSON YP, ACKLIN P, BISCHOFF S et al.:N-phosphonoalky1-5-aminomethylquinoxaline-2,3-dione: in vivo active AMPA and NMDA (glycine) antagonists. Bioorg. Med. Chem. Lett. (1999) 9:249–254.
   PubMed Web of Science ®Google Scholar
• MICHELI F, CUGOLA A, DONATI D et al.:2, 3-dihydro-6,7-dichloro-pyrido [2,3- b] py razine-8-oxide as selective glycine antagonist with In vivo activity. Bioorg. Med. Chem. (1997) 5:2129–2132.
   PubMed Web of Science ®Google Scholar
• PARSONS CG, DANYSZ W, QUACK G et al.: Novel systemically active antagonists of the glycine site of the N-methyl-d-aspartate receptor: electrophysio-logical, biochemical and behavioral characterization. J. Pharmacol. Exp. Ther. (1997) 283:1264–1275.
   PubMed Web of Science ®Google Scholar
• ••Description of the pharmacological activity of the Merzcompounds.
   Google Scholar
• WLAZ P, LOESCHER W: Weak anticonvulsivant effects oftwo novel glycineB receptor antagonists in the amygdala-kindling model in rats. Eur. J. Pharmacol (1998) 342:39–46.
   PubMedGoogle Scholar
• LAZAREWICZ JVV, GADAMSKI R, PARSON CG, DANYSZ W:Protection against post-iscaemic neuronal loss in gerbil hippocampal CA1 by glycineB and AMPA antago-nists. J. Neural Transm. (1997) 104:1249–1254.
   PubMed Web of Science ®Google Scholar
• WENK GL, BAKER LM, HAUSS-WEGRZYNIAK B, DANYSZW, STOEHR JD: Novel glycineB antagonists show neuroprotective activity in vivo. Amino Acids (1998) 14:223–226.
   PubMed Web of Science ®Google Scholar
• WENK GL, BAKER LM, STOEHR JD, HAUSS-WEGRZYNIAKB, DANYSZ W: Neuroprotection by novel antagonists at the NMDA receptor channel and glycineB sites. Eur. J. Pharmacol (1998) 347:183–187.
   PubMed Web of Science ®Google Scholar
• DANYSZ W, PARSONS CG, KARCZ-KUBICHA M et al: GlycineB antagonists as potential therapeutic agents. Previous hopes and present reality. Amino Adds (1998) 14:235–239.
   Google Scholar
• BARE TM: Pyridazino [4,5 -blquinolinediones: novel glycine/N-methyl-D-aspartate antagonists for the treatment of stroke. J. Heterocycl Chem. (1998) 35:1171–1186.
   Web of Science ®Google Scholar
• ••Detailed description of the SAR and the biological profile ofthe pyridazinoquinolines that include ZD9379.
   Google Scholar
• TAKANO K, TATLISUMAK T, FORMATO JE et al.: Glycinesite antagonist attenuates infarct size in experimental focal ischemia. Stroke (1997) 28:1255–1263.
   PubMed Web of Science ®Google Scholar
• TATLISUMAK T, TAKANO K, MEILER MR, FISHER M: A glycine site antagonist, ZD9379, reduces number of spreading depression and infarct size in rats with permanent middle cerebral artery occlusion. Stroke (1998) 29:190–195.
   PubMed Web of Science ®Google Scholar
• HICKS CA, WARD MA, RAGUMOORTHY N et al.: Evalua-tion of glycine antagonists of the NMDA receptor in global cerebral ischaemia. Brain Research (1999) 819:65–74.
   PubMed Web of Science ®Google Scholar